Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupropion for Adolescent Smoking Cessation
NCT00248118Phase 3Terminated
- Sponsor
- National Institute on Drug Abuse
- Start
- Jan 2005
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bupropion in tobacco dependence (2 arms), sponsored by National Institute on Drug Abuse. Primary endpoints: Clinical efficacy and safety of bupropion at 7 weeks, Smoking cessation rate at 7 weeks and 1 more. Started Jan 2005; status: terminated.
02
Drugs
bupropion
03
Conditions
tobacco dependence
Beyond the preview
Go deeper on NCT00248118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00248118.